🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseMy liver enzyme journey — July 2024 Page 3

My liver enzyme journey — July 2024

KetoKyle Sun, Mar 15, 2026 at 4:50 AM 32 replies 1,320 viewsPage 3 of 7
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Mar 16, 2026 at 5:54 AM#11
Dr.ReproEndo said:
The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

Correct as far as it goes. The part it does not cover is what to do when the honest answer is "not enough data", which is more often than anyone likes.

48 21julia.endo, JessicaM_2024, TomFromTexas and 45 others
Reply Quote Save Share Report
kevin_tulsa
Member
489
2,123
Jun 2024
Tulsa, OK
Mar 16, 2026 at 9:32 AM#12
PurityPaulOR said:
Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 325 dB/m (moderate steatosis) and stiffness 9.8 kPa (possible…

That reframing is the part I needed.

Last edited: Mar 16, 2026 at 11:32 AM
49 22Dr.RheumBOS, greg_boulder, quinn_sf and 46 others
Reply Quote Save Share Report
adam_van
Member
212
890
Nov 2024
Vancouver, CA
Mar 16, 2026 at 1:10 PM#13
Dr.ReproEndo said:
The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Filing an objection on the n=1 problem. Personal experience is genuine evidence about one person and very weak evidence about anybody else, and this thread keeps promoting the first into the second.

50 23LindaRN_retired, tommy_boulder, hyun_seoul and 47 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Mar 16, 2026 at 4:48 PM#14

Adding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Last edited: Mar 16, 2026 at 6:48 PM
1 24KarenAZ_mom
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Mar 16, 2026 at 8:26 PM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Tagging this one for the weekly digest.

2 0PurityPaulOR, MaxMetOK
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register